Open AccessAntimicrobial Properties of MX-2401, an Expanded-Spectrum Lipopeptide Active in the Presence of Lung Surfactant
Author(s) -
Dominique Dugourd,
Haiyan Yang,
Melissa Elliott,
Raymond Siu,
Jacob J. Clement,
Suzana K. Straus,
Robert E. W. Hancock,
Evelina Rubinchik
Publication year - 2011
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00322-11
Subject(s) - lipopeptide , pulmonary surfactant , antimicrobial , chemistry , microbiology and biotechnology , lung , medicine , biology , bacteria , biochemistry , genetics
MX-2401 is an expanded-spectrum lipopeptide antibiotic selective for Gram-positive bacteria that is a semisynthetic analog of the naturally occurring lipopeptide amphomycin. It was active againstEnterococcus spp., including vancomycin-sensitiveEnterococcus (VSE),vanA -,vanB -, andvanC -positive vancomycin-resistantEnterococcus (VRE), linezolid- and quinupristin-dalfopristin-resistant isolates (MIC90 of 4 μg/ml), methicillin-resistantStaphylococcus aureus (MRSA) and methicillin-sensitiveS. aureus (MSSA) (MIC90 of 2 μg/ml), coagulase-negative staphylococci, including methicillin-sensitiveStaphylococcus epidermidis (MSSE) and methicillin-resistantS. epidermidis (MRSE) (MIC90 of 2 μg/ml), andStreptococcus spp. including viridans group streptococci, and penicillin-resistant, penicillin-sensitive, penicillin-intermediate and macrolide-resistant isolates ofStreptococcus pneumoniae (MIC90 of 2 μg/ml). MX-2401 demonstrated a dose-dependent postantibiotic effect varying from 1.5 to 2.4 h. Furthermore, MX-2401 was rapidly bactericidal at 4 times the MIC againstS. aureus andEnterococcus faecalis , with more than 99.9% reduction in viable bacterial attained at 4 and 24 h, respectively. The MICs of MX-2401 against MRSA, MSSA, VSE, and VRE strains serially exposed for 15 passages to sub- to supra-MICs of MX-2401 remained within three dilutions of the original MIC. In contrast to that of the lipopeptide daptomycin, the antibacterial activity of MX-2401 was not affectedin vitro by the presence of lung surfactant, and MX-2401 was activein vivo in the bronchial-alveolar pneumonia mouse model, in which daptomycin failed to show any activity. Moreover, the activity of MX-2401 was not as strongly dependent on the Ca2+ concentration as is the activity of daptomycin. In conclusion, MX-2401 is a promising new-generation lipopeptide for the treatment of serious infections with Gram-positive bacteria, including hospital-acquired pneumonia.